Biogen completed the acquisition of Alcyone Therapeutics for its ThecaFlex DRx implantable device, paying $50M upfront with another $35M upon FDA approval. This signals a strategic focus on integrating new medical device technology, creating needs for manufacturing, supply chain, and commercialization support for the new asset.
Filing excerpt
In November 2025 we completed the acquisition of all of the issued and outstanding shares of Alcyone Therapeutics, Inc., a clinical-stage biotechnology company focused on pediatric care through precision CNS therapeutics and dosing platforms.
What this signalsIntegration work after a deal often opens needs for new systems and services.
Technologies
sec-10kacquisitionCompletedGet every 10-K signal for Biogen and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Biogen this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/2a34cbd6-5b57-49a3-beb0-bbb35dd3e33c returns this record as JSON. POST /v1/companies/enrich returns every signal for biogen.com.
{
"signal_id": "2a34cbd6-5b57-49a3-beb0-bbb35dd3e33c",
"signal_type": "sec-10k",
"signal_subtype": "acquisitionCompleted",
"detected_at": "2026-02-10T07:50:47.777+00:00",
"company": {
"name": "Biogen",
"domain": "biogen.com"
},
"data": {
"detail": "Biogen completed the acquisition of Alcyone Therapeutics for its ThecaFlex DRx implantable device, paying $50M upfront with another $35M upon FDA approval. This signals a strategic focus on integrating new medical device technology, creating needs for manufacturing, supply chain, and commercialization support for the new asset.",
"metrics": {
"timeframe": "current_year",
"dollar_context": "Total consideration for Alcyone Therapeutics acquisition, including upfront and milestone payment.",
"dollar_millions": 85
},
"summary": "Biogen acquired Alcyone Therapeutics for ~$85M to gain new drug delivery device technology",
"excerpts": "In November 2025 we completed the acquisition of all of the issued and outstanding shares of Alcyone Therapeutics, Inc., a clinical-stage biotechnology company focused on pediatric care through precision CNS therapeutics and dosing platforms.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm",
"filing_date": "2026-02-06",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Active integration needs",
"signal_category": "strategic",
"technologies_mentioned": [
"medical device",
"ASOs"
]
}
}
curl https://signals.autobound.ai/v1/signals/2a34cbd6-5b57-49a3-beb0-bbb35dd3e33c \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"biogen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.